To address this issue, we targeted RAF1 more specifically via shRNA and CRISPR and found that, in both cases, HCMV infection was reduced, albeit to a smaller extent than with pharmacological treatment (Fig. 6 and 7). The gene discussed is RAF1; the disease is cytomegalovirus infection.